134 related articles for article (PubMed ID: 34577783)
1. Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer.
Voutsadakis IA
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577783
[No Abstract] [Full Text] [Related]
2. Chromosome 20q11.21 Amplifications in Colorectal Cancer.
Voutsadakis IA
Cancer Genomics Proteomics; 2021; 18(3 Suppl):487-496. PubMed ID: 33994370
[TBL] [Abstract][Full Text] [Related]
3. 20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome.
Smith LT; Mayerson J; Nowak NJ; Suster D; Mohammed N; Long S; Auer H; Jones S; McKeegan C; Young G; Bos G; Plass C; Morrison C
Genes Chromosomes Cancer; 2006 Oct; 45(10):957-66. PubMed ID: 16847944
[TBL] [Abstract][Full Text] [Related]
4. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
[TBL] [Abstract][Full Text] [Related]
5. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression.
Sillars-Hardebol AH; Carvalho B; Tijssen M; Beliën JA; de Wit M; Delis-van Diemen PM; Pontén F; van de Wiel MA; Fijneman RJ; Meijer GA
Gut; 2012 Nov; 61(11):1568-75. PubMed ID: 22207630
[TBL] [Abstract][Full Text] [Related]
6. TPX2 prompts mitotic survival via the induction of BCL2L1 through YAP1 protein stabilization in human embryonic stem cells.
Kim YJ; Go YH; Jeong HC; Kwon EJ; Kim SM; Cheong HS; Kim W; Shin HD; Lee H; Cha HJ
Exp Mol Med; 2023 Jan; 55(1):32-42. PubMed ID: 36596852
[TBL] [Abstract][Full Text] [Related]
7. Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL.
Nguyen HT; Geens M; Mertzanidou A; Jacobs K; Heirman C; Breckpot K; Spits C
Mol Hum Reprod; 2014 Feb; 20(2):168-77. PubMed ID: 24217388
[TBL] [Abstract][Full Text] [Related]
8. The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion.
Mackinnon RN; Selan C; Wall M; Baker E; Nandurkar H; Campbell LJ
Genes Chromosomes Cancer; 2010 Nov; 49(11):998-1013. PubMed ID: 20645416
[TBL] [Abstract][Full Text] [Related]
9. Increased copy number of imprinted genes in the chromosomal region 20q11-q13.32 is associated with resistance to antitumor agents in cancer cell lines.
Krushkal J; Vural S; Jensen TL; Wright G; Zhao Y
Clin Epigenetics; 2022 Dec; 14(1):161. PubMed ID: 36461044
[TBL] [Abstract][Full Text] [Related]
10. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
[No Abstract] [Full Text] [Related]
11. Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Watanabe T; Imoto I; Katahira T; Hirasawa A; Ishiwata I; Emi M; Takayama M; Sato A; Inazawa J
Jpn J Cancer Res; 2002 Oct; 93(10):1114-22. PubMed ID: 12417041
[TBL] [Abstract][Full Text] [Related]
12. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
Valtorta E; Misale S; Sartore-Bianchi A; Nagtegaal ID; Paraf F; Lauricella C; Dimartino V; Hobor S; Jacobs B; Ercolani C; Lamba S; Scala E; Veronese S; Laurent-Puig P; Siena S; Tejpar S; Mottolese M; Punt CJ; Gambacorta M; Bardelli A; Di Nicolantonio F
Int J Cancer; 2013 Sep; 133(5):1259-65. PubMed ID: 23404247
[TBL] [Abstract][Full Text] [Related]
13. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
[TBL] [Abstract][Full Text] [Related]
14. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.
Kim YH; Girard L; Giacomini CP; Wang P; Hernandez-Boussard T; Tibshirani R; Minna JD; Pollack JR
Oncogene; 2006 Jan; 25(1):130-8. PubMed ID: 16116477
[TBL] [Abstract][Full Text] [Related]
15. YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer.
Jerhammar F; Johansson AC; Ceder R; Welander J; Jansson A; Grafström RC; Söderkvist P; Roberg K
Oral Oncol; 2014 Sep; 50(9):832-9. PubMed ID: 24993889
[TBL] [Abstract][Full Text] [Related]
16. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the topoisomerase I locus in human colorectal cancer.
Boonsong A; Marsh S; Rooney PH; Stevenson DA; Cassidy J; McLeod HL
Cancer Genet Cytogenet; 2000 Aug; 121(1):56-60. PubMed ID: 10958942
[TBL] [Abstract][Full Text] [Related]
18. Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
Sandhu J; Wang C; Fakih M
J Natl Compr Canc Netw; 2020 Feb; 18(2):116-119. PubMed ID: 32023524
[TBL] [Abstract][Full Text] [Related]
19.
Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
[TBL] [Abstract][Full Text] [Related]
20. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes.
Holzmann K; Kohlhammer H; Schwaenen C; Wessendorf S; Kestler HA; Schwoerer A; Rau B; Radlwimmer B; Döhner H; Lichter P; Gress T; Bentz M
Cancer Res; 2004 Jul; 64(13):4428-33. PubMed ID: 15231651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
